Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors

Kai Lin Xu; Jun Nian Zheng

Status and phase

Unknown

Phase 1

Conditions

B-cell Lymphoma

Chronic Lymphocytic Leukemia

Acute Lymphoblastic Leukemia

Treatments

Drug: hCD19.IL15.CAR-iNKT

Study type

Interventional

Funder types

Other

Identifiers

NCT04814004

XYFY2021-KL062

Details and patient eligibility

About

This study aims to evaluate the safety and feasibility of hCD19.IL15.CAR-iNKT cells in treating patients with relapsed/refractory/high-risk B-cell tumors.

Full description

CD19 CAR-T has been shown to treat a variety of refractory or recurrent B-cell tumors. Because most CAR-T cells are generated from the patient's own T cells and are individualized products, and there are individual differences between patients, the generation of customized CAR-T cells is an expensive and time-consuming process. Universal CAR- iNKT cells are an ideal product for cell therapy. In this study, we prepared universal iNKT cells expressing hCD19 CAR and IL-15 to treat refractory, relapsed, or high-risk B-cell tumors.

Enrollment

20 estimated patients

Sex

All

Ages

5 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female patients aged 5-70 years;
The patient's ECOG score was ≤2, and the expected survival time of > was 12 weeks.
The patient was diagnosed with B-cell tumor by pathological and histological examination and had no effective treatment options, such as recurrence after chemotherapy or hematopoietic stem cell transplantation. Or the patient voluntarily chooses the infusion of CAR-INKT cells as the first treatment.
B cell tumors include the following three types:
1. B-cell acute lymphocytic leukemia (B-ALL);
2. Inert B-cell lymphoma (CLL, FL, MZL, LPL, HCL);
3. Aggressive B-cell lymphoma (DLBCL, BL, MCL);
Subject:
1. Residual lesions remain after primary treatment and are not suitable for HSCT (Auto/Allo-HSCT);
2. relapse after complete response (CR1) and unsuitable for allogeneic/autologous HSCT;
3. Patients with high risk factors;
4. relapse or no remission after hematopoietic stem cell transplantation or cellular immunotherapy.
having measurable or evaluable lesions;
The main tissues and organs of the patient function well:
1. Liver function: ALT/AST < 3 times the upper limit of normal (ULN);
2. Renal function: creatinine < 220μmol/L;
3. Lung function: indoor oxygen saturation ≥95%;
4. Heart function: left ventricular ejection fraction (LVEF) ≥40%.
Patients or their legal guardians voluntarily participate and sign the informed consent.

Exclusion criteria

Pregnant or lactating women, or women who plan to become pregnant within six months;
Infectious diseases (e.g. HIV, active hepatitis B or C infection, active tuberculosis, etc.);
GVHD;
Abnormal vital signs and failure to cooperate with the examination;
People with mental or mental illness who are unable to cooperate with treatment and efficacy evaluation;
People with high allergic constitution or severe allergic history, especially those allergic to IL-2;
Subjects with systemic infection or severe local infection need anti-infection therapy;
Complicated with dysfunction of heart, lung, brain, liver, kidney and other important organs;
Any unstable systemic disease: including but not limited to unstable angina pectoris, cerebrovascular accident or transient cerebral ischemia (within 6 months before screening), myocardial infarction (within 6 months before screening), congestive heart failure (NYHA classification ≥III);
Doctors believe that there are other reasons for not being included in treatment.